- Home
- AIMD vs PULM Comparison
AIMD vs PULM Comparison
Compare AIMD & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIMD
- PULM
- Stock Information
- Founded
- AIMD 1984
- PULM 2003
- Country
- AIMD United States
- PULM United States
- Employees
- AIMD N/A
- PULM N/A
- Industry
- AIMD Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- AIMD Health Care
- PULM Health Care
- Exchange
- AIMD Nasdaq
- PULM Nasdaq
- Market Cap
- AIMD 16.9M
- PULM 18.3M
- IPO Year
- AIMD N/A
- PULM N/A
- Fundamental
- Price
- AIMD $3.64
- PULM $4.78
- Analyst Decision
- AIMD
- PULM
- Analyst Count
- AIMD 0
- PULM 0
- Target Price
- AIMD N/A
- PULM N/A
- AVG Volume (30 Days)
- AIMD 68.9K
- PULM 17.9K
- Earning Date
- AIMD 11-14-2025
- PULM 10-16-2025
- Dividend Yield
- AIMD N/A
- PULM N/A
- EPS Growth
- AIMD N/A
- PULM N/A
- EPS
- AIMD N/A
- PULM N/A
- Revenue
- AIMD $110,870.00
- PULM $3,000.00
- Revenue This Year
- AIMD N/A
- PULM N/A
- Revenue Next Year
- AIMD N/A
- PULM $134.88
- P/E Ratio
- AIMD N/A
- PULM N/A
- Revenue Growth
- AIMD 70.25
- PULM N/A
- 52 Week Low
- AIMD $2.00
- PULM $1.97
- 52 Week High
- AIMD $5.00
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- AIMD 47.65
- PULM 51.99
- Support Level
- AIMD $3.39
- PULM $4.55
- Resistance Level
- AIMD $4.44
- PULM $5.24
- Average True Range (ATR)
- AIMD 0.24
- PULM 0.27
- MACD
- AIMD -0.06
- PULM 0.02
- Stochastic Oscillator
- AIMD 25.71
- PULM 59.02
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).